The U.S. Food and Drug Administration (FDA) serves as the primary regulatory authority for drugs entering the market. Its decisions to approve or reject a product are pivotal for biotechnology firms and often trigger significant stock market movements.
​
Leveraging our deep clinical expertise and a standardized, evidence-based approach, we deliver high-confidence assessments regarding the likelihood of FDA approval for clinical-stage compounds